Subcutaneous rivipansel: Phase I started

Pfizer began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate subcutaneous rivipansel in about 27 healthy volunteers. Subjects will receive single ascending doses of rivipansel in a 3- or 4-period crossover, after which the subjects will receive ascending doses of rivipansel twice daily for 7 days. ...